« Return to News | Clinical Intelligence

Adamis looks to test prostate cancer drug on humans

Monday, March 14, 2011 01:48 PM

Adamis Pharmaceuticals is seeking permission from federal regulators to begin testing APC-100, an experimental prostate cancer drug, on human patients for the first time, according to the San Diego Union-Tribune.

The Del Mar company’s Investigational New Drug application with the FDA seeks to recruit 30 men with castrate-resistant prostate cancer for a phase 1 trial. The testing will be conducted through the University of Wisconsin Carbone Cancer Center in Madison and Wayne State University’s Karmanos Cancer Institute in Detroit.

The oral drug, an organic molecule that was discovered by researchers at the Carbone center, is designed to block male hormones tied to prostate cancer in men who have become resistant to other hormone-blocking therapies.

In tests on mice with the disease, the drug worked 90% of the time in comparison to standard treatments that worked 55% of the time, the company said. The drug previously received a Rapid Access to Preventive Intervention Development grant from the National Cancer Institute.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.